

Serum peptide patterns for diagnostics of intracranial hemorrhagic stroke in humans and differential diagnosis of intracranial hemorrhagic stroke from acute ischemic stroke

About technology

Over the years, the analysis of the serum peptidome has been consistently limited for various reasons: enormous complexity, high protein content, concentration, instability of low-abundance proteins or secreted peptides, depletion steps and precipitation methods. All these problems occurring at different stages ultimately lead to a significant loss of the endogenous peptide biomarker. Moreover, the coexistence of these high abundance proteins hinders the efficient detection of low or very low abundance peptides. With these problems in mind, ICCVS has developed a novel approach without depleting or precipitating the serum proteome and a direct isolation platform for rapid, comprehensive and reproducible profiling of serum peptides by mass spectrometry. The invented innovation is globally applicable for the screening of significant peptides from all types of patient blood samples.



TRL 4

Research Team:

PhD Sachin Kote
Prof. Natalia Marek-Trzonkowska
PhD Artur Piróg
PhD Jakub Faktor
Prof. UG, dr hab. Paulina Czaplewska
mgr Marc Muller

IP protection

The invention is the subject of a European patent application
EP22216488.1; EP22216509.4;
PCT/EP2023/085452 and
PCT/EP2023/085453

Implementation progress

TRL 4 –Technology validated in laboratory conditions

Cooperation opportunities

- Licensing agreement
- Transfer of ownership
- Spin off



International Centre for
**Cancer Vaccine
Science**